Ackman: Valeant's main problem is PR, not fraud
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Valeant Pharma (VRX) falls below $100 again
October 30, 2015 11:58 AM EDTValeant Pharma (NYSE: VRX) falls below $100 again
... MoreBill Ackman said their average cost on Valeant Pharma (VRX) is $186
October 30, 2015 11:11 AM EDTOn Valeant Pharma (NYSE: VRX) call, Bill Ackman said their average cost is $186
... More